Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

OMER
Omeros Corporation
stock NASDAQ

At Close
May 8, 2025 3:59:57 PM EDT
6.30USD-0.787%(-0.05)399,767
0.00Bid   0.00Ask   0.00Spread
Pre-market
May 7, 2025 8:41:30 AM EDT
6.46USD+1.732%(+0.11)0
After-hours
May 8, 2025 4:38:30 PM EDT
6.31USD+0.157%(+0.01)5,338
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 21, 2022
03:55PM EST  Omeros Option Alert: Feb 18 $7 Calls Sweep (45) near the Ask: 832 @ $0.4 vs 314 OI; Earnings 2/28 After Close [est] Ref=$5.295   Benzinga
Jan 20, 2022
08:28AM EST  The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug   Benzinga
Jan 19, 2022
10:26PM EST  Omeros Corp. (OMER) confirmed Wednesday that earlier this month the company submitted to the U.S. Food and Drug Administration its response to the Agency's complete Response Letter or CRL for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy or HSCT-TMA.   RTTNews
05:56PM EST  Omeros Confirms Submission Of Response To FDA Regarding BLA For Narsoplimab In Treatment Of HSCT-TMA   Benzinga
05:52PM EST  Omeros Confirms Submission of Response to FDA Regarding the BLA for Narsoplimab in the Treatment of HSCT-TMA   Business Wire
Dec 23, 2021
09:13AM EST  Omeros Completes Sale Of OMIDRIA Franchise To Rayner Surgical   RTTNews
Dec 2, 2021
12:25PM EST  Omeros Shares Quiet; Cantor Sets $34 Price Target   Benzinga
10:32AM EST  Shares of Omeros Corporation (OMER) are climbing more than 5% Thursday morning after the company announced agreement to sell Omeros' FDA-approved product, Omidria to Rayner Surgical Group Limited in a transaction valued more than $1 billion.   RTTNews
07:51AM EST  Biopharmaceutical company Omeros Corp. (OMER) announced Thursday that it has entered into a definitive agreement for the sale of OMIDRIA to Rayner Surgical Group Ltd.   RTTNews
07:36AM EST  Omeros To Sell OMIDRIA Franchise To Rayner Surgical In Transaction Valued In Excess Of $1 Bln   RTTNews
07:33AM EST  Omeros Announces Agreement To Sell OMIDRIA Franchise To Rayner Surgical In A Transaction Valued In Excess Of $1B   Benzinga
07:30AM EST  Omeros Announces Agreement to Sell OMIDRIA(r) Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion   Business Wire
Nov 9, 2021
05:16PM EST  Omeros Q3 EPS $(0.36) Beats $(0.52) Estimate, Sales $30.00M Beat $26.96M Estimate   Benzinga
05:05PM EST  Omeros: Q3 Earnings Insights   Benzinga
04:02PM EST  Omeros Corporation Reports Third Quarter 2021 Financial Results   Business Wire
11:42AM EST  The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data   Benzinga
11:25AM EST  Earnings Scheduled For November 9, 2021   Benzinga
Nov 8, 2021
10:01AM EST  Earnings Outlook For Omeros   Benzinga
Nov 5, 2021
04:57PM EDT  Omeros' Narsoplimab Shows Improved, Stabilized Renal Function At Three Years   Benzinga
09:44AM EDT  Omeros Announces Results From Nearly Three-Year Follow-Up Of Patients In Phase 2 IgA Nephropathy Trial; Says 'Data Show Improvement And Stabilization In Renal Function'   Benzinga
09:43AM EDT  Omeros Highlights Presentation Of Data At Annual Meeting Of the American Society Of Nephrology Yesterday   Benzinga
08:48AM EDT  Omeros : Long-term Data Supportive Of Key Role For Lectin Pathway Inhibition In Future Management Of Patients With IgAN   RTTNews
08:40AM EDT  Omeros Announces Results From Nearly Three-Year Follow-up of Patients in Phase 2 IgA Nephropathy Trial   Business Wire
08:30AM EDT  Omeros' Narsoplimab Stabilized Kidney Function and Reduced Urinary Complement Proteins in a Patient with IgA Vasculitis   Business Wire
Nov 4, 2021
08:30AM EDT  Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2021   Business Wire
Oct 19, 2021
08:21AM EDT  10 Biggest Price Target Changes For Tuesday   Benzinga
06:51AM EDT  HC Wainwright & Co. Maintains Buy on Omeros, Lowers Price Target to $12   Benzinga
Oct 18, 2021
02:37PM EDT  Mid-Afternoon Market Update: Dow Falls 70 Points; Evolving Systems Shares Spike Higher   Benzinga
12:56PM EDT  Mid-Day Market Update: Nasdaq Rises 50 Points; Revance Therapeutics Shares Plummet   Benzinga
10:28AM EDT  Mid-Morning Market Update: Markets Mostly Lower; Albertsons Tops Q2 Estimates   Benzinga
06:48AM EDT  Omeros Corp. (OMER), a commercial-stage biopharmaceutical company, Monday said it has received a Complete Response Letter or CRL from the U.S. Food and Drug Administration. The CRL is regarding its Biologics License Application or BLA for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy or HSCT-TMA.   RTTNews
06:34AM EDT  Omeros Receives CRL From FDA For BLA For Narsoplimab In The Treatment Of HSCT-TMA   RTTNews
06:30AM EDT  Omeros Receives Complete Response Letter From FDA For Biologics License Application For Narsoplimab In The Treatment Of HSCT-TMA   Benzinga
Oct 12, 2021
08:13AM EDT  The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology   Benzinga
Oct 11, 2021
03:51PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation (Omeros or the Company) (NASDAQ:OMER). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Oct 8, 2021
11:52AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For October 8, 2021   Benzinga
05:56AM EDT  JP Morgan Downgrades Omeros to Underweight   Benzinga
Oct 6, 2021
07:33AM EDT  The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal   Benzinga
07:13AM EDT  HC Wainwright & Co. Maintains Buy on Omeros, Lowers Price Target to $19   Benzinga
Oct 5, 2021
08:01AM EDT  The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout   Benzinga
Oct 4, 2021
02:32PM EDT  Mid-Afternoon Market Update: Dow Drops 375 Points; Elmira Savings Bank Shares Spike Higher   Benzinga
12:17PM EDT  Mid-Day Market Update: Nasdaq Down 2%; Xenon Pharmaceuticals Shares Jump   Benzinga
10:02AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For October 4, 2021   Benzinga
09:08AM EDT  Maxim Group Downgrades Omeros to Hold   Benzinga
Oct 3, 2021
08:51PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation (Omeros or the Company) (NASDAQ:OMER). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
02:21PM EDT  The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs and More   Benzinga
Oct 1, 2021
02:51PM EDT  Mid-Afternoon Market Update: Nasdaq Rises Over 100 Points; Biomerica Shares Spike Higher   Benzinga
02:29PM EDT  Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates   Benzinga
12:47PM EDT  Mid-Day Market Update: Dow Surges 300 Points; Omeros Shares Plummet   Benzinga
10:21AM EDT  Mid-Morning Market Update: Markets Mostly Higher; ISM Manufacturing Index Rises In September   Benzinga
09:26AM EDT  Omeros: FDA Finds Deficiencies In BLA For Narsoplimab;   RTTNews
09:01AM EDT  Omeros : FDA Identifies Deficiencies In BLA For Narsoplimab In Treatment Of HSCT-TMA; Stock Plunges   RTTNews
08:58AM EDT  UPDATE: Omeros Says 'does not currently expect any such resolution to occur by the October 17, 2021 target action date under the Prescription Drug User Fee Act (PDUFA).'; Says Is Evaluating Next Steps   Benzinga
08:56AM EDT  Omeros Announces FDA Has Identified Deficiencies In BLA For Narsoplimab That Preclude Discussion Of Labeling And Post-Marketing Requirements At This Time   Benzinga
08:55AM EDT  Omeros Provides Regulatory Update on Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA   Business Wire
Sep 27, 2021
10:04AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2021   Benzinga
05:08AM EDT  JP Morgan Initiates Coverage On Omeros with Neutral Rating, Announces Price Target of $15   Benzinga
Sep 20, 2021
11:02AM EDT  Looking Into Omeros's Return On Capital Employed   Benzinga
Aug 9, 2021
04:58PM EDT  Omeros: Q2 Earnings Insights   Benzinga
04:37PM EDT  Omeros Q2 EPS $(0.46) Beats $(0.57) Estimate, Sales $28.82M Beat $24.27M Estimate   Benzinga
04:02PM EDT  Omeros Corporation Reports Second Quarter 2021 Financial Results   Business Wire
04:11AM EDT  Earnings Scheduled For August 9, 2021   Benzinga
Aug 3, 2021
08:30AM EDT  Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2021   Business Wire
Jun 24, 2021
09:49AM EDT  Return On Capital Employed Overview: Omeros   Benzinga
Jun 18, 2021
08:59AM EDT  WBB Securities Maintains Strong Buy on Omeros, Raises Price Target to $100   Benzinga
Jun 14, 2021
12:45PM EDT  Omeros' Narsoplimab Associated With Improvement In Organ Function In Stem Cell Transplant Patients   Benzinga
08:41AM EDT  Omeros Presents Data On Organ Function Improvement From Its Pivotal Trial Of Narsoplimab   RTTNews
08:32AM EDT  Omeros Highlights Presentation Of Narsoplimab Pivotal Trial Data In Oral Presentation At 2021 Annual Congress Of European Hematology Association   Benzinga
08:30AM EDT  Omeros' Narsoplimab Pivotal Trial Data Shared in Oral Presentation at 2021 Annual Congress of the European Hematology Association   Business Wire
Jun 10, 2021
08:48AM EDT  Omeros Publishes Detailing Mechanism Of Action Of PDE7 In Nicotine Addiction   RTTNews
08:45AM EDT  Omeros Announces Publication Detailing the Mechanism of Action of PDE7 In Nicotine Addiction   Business Wire
Jun 9, 2021
05:00PM EDT  Omeros to Present at the BofA 2021 Napa BioPharma Virtual Conference   Business Wire
09:13AM EDT  Omeros Corp. (OMER) announced preliminary results from the Phase 1 clinical trial of its MASP-3 inhibitor OMS906. The ongoing trial is designed as a randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of intravenous (IV) and subcutaneous (SC) administration of OMS906 to healthy adult volunteers.   RTTNews
08:55AM EDT  Omeros Announces Preliminary Results From Phase 1 Trial Of OMS906 In PK, PD; OMS906 Well Tolerated At All Doses Tested   RTTNews
08:47AM EDT  Omeros Announces Preliminary Results From Phase 1 Clinical Trial Of OMS906; Says Results Show Good Safety, PK/PD Profile   Benzinga
08:45AM EDT  Omeros Announces Preliminary Results from Phase 1 Clinical Trial of OMS906   Business Wire
Jun 8, 2021
11:35AM EDT  Omeros: Return On Capital Employed Insights   Benzinga
Jun 7, 2021
10:40PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation (Omeros or the Company) (NASDAQ:OMER). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
May 28, 2021
12:00PM EDT  Omeros's Narsoplimab Shows Encouraging Action In Critically Ill COVID-19 Patients   Benzinga
09:23AM EDT  Omeros Corp. (OMER) announced preliminary results from the second cohort of critically ill COVID-19 patients treated with narsoplimab in Bergamo, Italy. 80% of the patients were recovered, survived and discharged.   RTTNews
08:46AM EDT  Omeros Issues Prelim. Results From Added Critically-Ill COVID-19 Patients Treated With Narsoplimab; 'Study Patients Comprise Second Cohort from Bergamo, Italy'   Benzinga
08:45AM EDT  Omeros Announces Preliminary Results from Additional Critically Ill COVID-19 Patients Treated with Narsoplimab   Business Wire
May 27, 2021
02:38PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation (Omeros or the Company) (NASDAQ:OMER). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
May 20, 2021
08:50AM EDT  Omeros: FDA To Require Additional Time To Review BLA For narsoplimab   RTTNews
08:46AM EDT  Omeros Announces Extension Of FDA Review Period For Narsoplimab In HSCT-TMA   Benzinga
May 13, 2021
08:41AM EDT  Omeros To Share Presentation At 2021 European Hematology Association Virtual Congress   Benzinga
08:34AM EDT  Omeros' Narsoplimab Pivotal Trial Data To Be Shared As Oral Presentation At European Hematology Association Congress   RTTNews
08:30AM EDT  Omeros' Narsoplimab Pivotal Trial Data to Be Shared as an Oral Presentation at the European Hematology Association Congress   Business Wire
May 10, 2021
04:53PM EDT  Omeros: Q1 Earnings Insights   Benzinga
04:06PM EDT  Omeros Q1 EPS $(0.57), Inline, Sales $21.60M Beat $18.74M Estimate   Benzinga
04:02PM EDT  Omeros Corporation Reports First Quarter 2021 Financial Results   Business Wire
04:09AM EDT  Earnings Scheduled For May 10, 2021   Benzinga
May 5, 2021
08:45AM EDT  Omeros Corporation to Announce First Quarter Financial Results on May 10, 2021   Business Wire
May 4, 2021
06:30AM EDT  Omeros Corp: CDC Approves ICD-10 Diagnosis Code For HSCT-TMA Diagnosis And For Narsoplimab Administration   RTTNews
05:45AM EDT  Omeros Corporation Announces Approval of ICD-10 Codes for HSCT-TMA Diagnosis and for Narsoplimab Administration   Business Wire
Apr 26, 2021
06:37AM EDT  HC Wainwright & Co. Maintains Buy on Omeros, Lowers Price Target to $32   Benzinga
Mar 23, 2021
09:29AM EDT  Omeros Corp. (OMER) and Quantum Leap Healthcare Collaborative said that they began dosing of patients with narsoplimab in the I-SPY COVID-19 Trial. The I-SPY COVID-19 Trial is an adaptive platform trial sponsored by Quantum Leap Healthcare Collaborative.   RTTNews
08:51AM EDT  Omeros And Quantum Leap Dose First Patients With Narsoplimab In I-SPY COVID-19 Trial   RTTNews
08:47AM EDT  Omeros, Quantum Leap Announce First Patients Dosed With Narsoplimab IN I-SPY COVID-19 Trial   Benzinga
08:45AM EDT  Omeros and Quantum Leap Announce First Patients Dosed with Narsoplimab in the I-SPY COVID-19 Trial   Business Wire
Mar 1, 2021
04:18PM EST  Recap: Omeros Q4 Earnings   Benzinga
04:04PM EST  Omeros Q4 EPS $(0.60) Beats $(0.64) Estimate, Sales $10.60M Miss $14.91M Estimate   Benzinga
04:02PM EST  Omeros Corporation Reports Fourth Quarter and Year-End 2020 Financial Results   Business Wire
03:51AM EST  Earnings Scheduled For March 1, 2021   Benzinga
Feb 27, 2021
09:04PM EST  The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings   Benzinga
Feb 25, 2021
09:37AM EST  Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on March 1, 2021   Business Wire
Feb 1, 2021
10:03AM EST  Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2021   Benzinga
07:56AM EST  UBS Initiates Coverage On Omeros with Buy Rating, Announces Price Target of $25   Benzinga
Jan 26, 2021
08:45AM EST  Omeros Hires Nadia Dac as Chief Commercial Officer   Business Wire
Jan 20, 2021
06:36AM EST  HC Wainwright & Co. Maintains Buy on Omeros, Raises Price Target to $34   Benzinga
Jan 19, 2021
12:38PM EST  Needham Maintains Hold Rating on Omeros Co., Cites Skepticism Regarding Unorthodox Development Process of Narsoplimab Treatment and Valuation on Market Share Potential   Benzinga
08:32AM EST  Omeros Announces Biologics License Application For Narsoplimab In HSCT-TMA Accepted For Priority Review By FDA   Benzinga
08:31AM EST  Biologics License Application for Narsoplimab in HSCT-TMA Accepted for Priority Review by U.S. FDA   Business Wire
Jan 11, 2021
04:30PM EST  Omeros to Present at the 39th Annual J.P. Morgan Healthcare Conference   Business Wire
Jan 4, 2021
06:19AM EST  HC Wainwright & Co. Maintains Buy on Omeros, Lowers Price Target to $31   Benzinga
Dec 3, 2020
10:12AM EST  Shares of bio pharmaceutical company Omeros Corporation (OMER) are climbing more than 13% Thursday morning and currently trading at $14.13.   RTTNews
07:44AM EST  Omeros: CMS Confirms Continued Separate Payment For FDA-Approved OMIDRIA In Ambulatory Surgery Centers   RTTNews
07:30AM EST  CMS Confirms Continued Separate Payment for Omeros' FDA-Approved OMIDRIA(r) in Ambulatory Surgery Centers   Business Wire
Nov 18, 2020
09:14AM EST  Omeros Reports Submission Of Its Biologics License Application To FDA For Narsoplimab In Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy   Benzinga
09:08AM EST  Omeros Submits Its BLA To FDA For Narsoplimab In HSCT-TMA   RTTNews
09:00AM EST  Omeros Submits its Biologics License Application to U.S. FDA for Narsoplimab in HSCT-TMA   Business Wire
Nov 12, 2020
09:55AM EST  Looking Into Omeros's Return On Capital Employed   Benzinga
Nov 11, 2020
11:49AM EST  Omeros Option Alert: Dec 18 $11 Calls Sweep (35) near the Ask: 286 @ $1.85 vs 44 OI; Ref=$11.12   Benzinga
Nov 9, 2020
04:46PM EST  Omeros: Q3 Earnings Insights   Benzinga
04:18PM EST  Omeros Q3 EPS $(0.66) Misses $(0.61) Estimate, Sales $26.11M Beat $19.11M Estimate   Benzinga
04:02PM EST  Omeros Corporation Reports Third Quarter 2020 Financial Results   Business Wire
04:13AM EST  Earnings Scheduled For November 9, 2020   Benzinga
Nov 8, 2020
03:58PM EST  The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions   Benzinga
12:47PM EST  The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs   Benzinga
Nov 5, 2020
07:00AM EST  Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2020   Business Wire
Oct 28, 2020
09:00AM EDT  Omeros Participates in Investor Conference Focused on COVID-19 Therapeutics in Development   Business Wire
Oct 22, 2020
08:18AM EDT  Omeros Announces Final Data From Its Pivotal Trial For Narsoplimab   RTTNews
08:00AM EDT  Omeros Reports Final Efficacy and Safety Data from the Narsoplimab Pivotal Trial in HSCT-TMA   Business Wire
07:52AM EDT  The Daily Biotech Pulse: FDA Vaccine Committee Meeting, Roche In $350M Deal for COVID-19 Treatment, Edwards Lifesciences Reports Q3 Beat   Benzinga
Oct 20, 2020
07:44AM EDT  B of A Securities Initiates Coverage On Omeros with Buy Rating, Announces Price Target of $21   Benzinga
Oct 16, 2020
08:33AM EDT  Omeros Highlights Presentation Of OMS906 Data At Complement-Based Drug Development Summit   Benzinga
08:30AM EDT  Omeros' OMS906 Data Presented at Complement-based Drug Development Summit   Business Wire
Oct 15, 2020
08:00AM EDT  Omeros Schedules Webcast to Present Final Efficacy Results from Narsoplimab BLA for the Treatment of HSCT-TMA   Business Wire
Oct 1, 2020
09:18AM EDT  Omeros Providers An Update To The Status Of Reimbursement For Its Cataract Surgery Drug OMIDRIA   Benzinga
09:00AM EDT  Omeros Provides Update on Separate Payment for OMIDRIA(r) in the ASCs   Business Wire
Sep 11, 2020
07:00AM EDT  Omeros to Present at the Cantor Virtual Global Healthcare Conference   Business Wire
Sep 3, 2020
09:43AM EDT  Omeros Shares Quiet; Omeros Highlights Co's Investigational Agent Narsoplimab Discussed At Demy-Colton Virtual Salon Series As 'Potentially Highly Effective Therapy' In Critically Ill COVID-19 Patients   Benzinga
09:38AM EDT  Expert Panel Points to Central Role of Endothelial Injury and Lectin Pathway Activation in Critically Ill COVID-19 Patients   Business Wire
Sep 1, 2020
08:16AM EDT  Wedbush Maintains Neutral on Omeros, Lowers Price Target to $12   Benzinga
Aug 31, 2020
09:41AM EDT  Omeros shares are trading higher after the FDA approved the company's new investigational drug application for its OMS906.   Benzinga
08:18AM EDT  How Does Omeros's Debt Look?   Benzinga
08:13AM EDT  Omeros' Investigational New Drug Application for OMS906 Approved by the FDA   Benzinga
08:12AM EDT  Omeros' Investigational New Drug Application For OMS906 Cleared By FDA   RTTNews
Aug 21, 2020
06:39AM EDT  HC Wainwright & Co. Maintains Buy on Omeros, Lowers Price Target to $32   Benzinga
Aug 12, 2020
06:36AM EDT  Omeros Prices Concurrent Underwritten Public Offerings Of 6.9 Of Shares Of Its Common Stock At A Public Offering Price Of $14.50 Per Share   Benzinga
06:35AM EDT  Omeros Reports Pricing Of Public Offerings Of 6.9 Mln Common Shares And $210 Mln 5.25% Convertible Senior Notes Due 2026   RTTNews
06:30AM EDT  Omeros Announces Pricing of Public Offerings   Business Wire
Aug 10, 2020
04:45PM EDT  04:45 Monday, August 10, 2020   RTTNews
04:16PM EDT  Omeros Reports $125M Common Stock, $200M Convertible Senior Notes Due 2026 Offering   Benzinga
04:12PM EDT  Omeros Announces Proposed Public Offerings of Common Stock and Convertible Senior Notes   Business Wire
04:08PM EDT  Omeros Q2 EPS $(0.61) Down From $(0.29) YoY, Sales $13.53M Down From $26.75M YoY   Benzinga
04:06PM EDT  Omeros Q2 Loss/share $0.61 Vs. Loss $0.29 Year Ago   RTTNews
04:01PM EDT  Omeros Corporation Reports Second Quarter 2020 Financial Results   Business Wire
02:32PM EDT  Mid-Afternoon Market Update: Dow Surges 300 Points; Omeros Shares Spike Higher   Benzinga
12:20PM EDT  Mid-Day Market Update: Crude Oil Rises 2%; Eastman Kodak Shares Plummet   Benzinga
11:41AM EDT  Omeros Rallies On COVID-19 Study Results: What You Should Know   Benzinga
11:35AM EDT  ROCE Insights For Omeros   Benzinga
10:27AM EDT  Mid-Morning Market Update: Markets Mostly Higher; Marriott Misses Q2 Expectations   Benzinga
10:01AM EDT  Shares of Omeros Corp. (OMER) are gaining almost 48 percent or $6.76 in Monday's morning trade at $20.89, after earlier touching a new 52-week high of $22.00 following positive data from a study evaluating Narsoplimab in the treatment of COVID-19 patients.   RTTNews
08:31AM EDT  Omeros Corp. (OMER) announced the recovery and survival of all patients in study evaluating narsoplimab for treatment of COVID-19 associated acute respiratory distress syndrome. The company is in discussions with U.S. government agencies regarding acceleration of narsoplimab manufacturing for use in COVID-19 patients.   RTTNews
07:52AM EDT  Omeros Reports Recovery Of Patients In Study Evaluating Narsoplimab For COVID-19 Patients With ARDS   RTTNews
07:42AM EDT  Omeros Says Co. 'is in discussions with U.S. government agencies regarding acceleration of narsoplimab manufacturing for use in COVID-19 patients'   Benzinga
07:42AM EDT  Omeros Says All Six Patients, Requiring Mechanical Ventilation Prior To Treatment, Recovered, Survived And Were Discharged From The Hospital; Says 'Narsoplimab treatment was associated with rapid and sustained improvement across all assessed markers'   Benzinga
07:42AM EDT  Omeros Corporation Reports Recovery And Survival Of All Patients In Study Evaluating Narsoplimab For Treatment Of COVID-19-Associated Acute Respiratory Distress Syndrome   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC